Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:DRUG NASDAQ:IPA NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$5.76-2.7%$6.41$4.34▼$12.38$367.75M0.45288,404 shs168,354 shsDRUGBright Minds Biosciences$50.83-1.3%$44.65$0.94▼$79.02$362.77M-6.1794,798 shs54,817 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.15$0.27▼$3.25$96.68M0.531.83 million shs1.97 million shsTVRDTvardi Therapeutics$40.28+0.2%$31.09$8.13▼$42.10$376.79M0.2467,629 shs39,157 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-2.15%-4.05%-8.64%-5.28%-32.11%DRUGBright Minds Biosciences-3.30%-10.36%+21.92%+92.60%+4,339.66%IPAImmunoPrecise Antibodies0.00%0.00%0.00%+19.03%+235.20%TVRDTvardi Therapeutics-0.12%+8.89%+29.15%+83.89%+4,017,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$5.76-2.7%$6.41$4.34▼$12.38$367.75M0.45288,404 shs168,354 shsDRUGBright Minds Biosciences$50.83-1.3%$44.65$0.94▼$79.02$362.77M-6.1794,798 shs54,817 shsIPAImmunoPrecise Antibodies$2.10+8.5%$2.15$0.27▼$3.25$96.68M0.531.83 million shs1.97 million shsTVRDTvardi Therapeutics$40.28+0.2%$31.09$8.13▼$42.10$376.79M0.2467,629 shs39,157 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-2.15%-4.05%-8.64%-5.28%-32.11%DRUGBright Minds Biosciences-3.30%-10.36%+21.92%+92.60%+4,339.66%IPAImmunoPrecise Antibodies0.00%0.00%0.00%+19.03%+235.20%TVRDTvardi Therapeutics-0.12%+8.89%+29.15%+83.89%+4,017,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.78Moderate Buy$22.00281.94% UpsideDRUGBright Minds Biosciences 3.11Buy$81.0059.35% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.0090.93% UpsideTVRDTvardi Therapeutics 2.60Moderate Buy$64.2559.51% UpsideCurrent Analyst Ratings BreakdownLatest IPA, TVRD, AURA, and DRUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025AURAAura BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TVRDTvardi TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/15/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.009/8/2025DRUGBright Minds BiosciencesBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.008/19/2025AURAAura BiosciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/19/2025DRUGBright Minds BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$85.008/13/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.007/14/2025TVRDTvardi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$62.007/11/2025TVRDTvardi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$52.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AIPAImmunoPrecise Antibodies$17.59M5.50N/AN/A$0.37 per share5.66TVRDTvardi TherapeuticsN/AN/AN/AN/A($3.02) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$86.92M-$1.96N/AN/AN/AN/A-64.44%-54.24%11/11/2025 (Estimated)DRUGBright Minds Biosciences-$2.06M-$0.93N/AN/AN/AN/A-20.96%-20.66%N/AIPAImmunoPrecise Antibodies-$21.69M-$0.68N/AN/AN/A-122.10%-40.62%-22.19%12/10/2025 (Estimated)TVRDTvardi Therapeutics-$70.87MN/A0.00∞N/A-678.79%-565.83%-66.71%N/ALatest IPA, TVRD, AURA, and DRUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025DRUGBright Minds Biosciences-$0.59-$0.53+$0.06-$0.53N/AN/A8/14/2025Q2 2025TVRDTvardi Therapeutics-$0.51-$1.00-$0.49-$1.00N/AN/A8/13/2025Q2 2025AURAAura Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A7/29/2025Q4 2025IPAImmunoPrecise Antibodies-$0.02-$0.04-$0.02-$0.04$7.89 million$5.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.3912.39DRUGBright Minds BiosciencesN/A86.6486.64IPAImmunoPrecise Antibodies0.492.081.85TVRDTvardi TherapeuticsN/A4.044.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%DRUGBright Minds Biosciences40.52%IPAImmunoPrecise Antibodies6.70%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences6.30%DRUGBright Minds Biosciences42.66%IPAImmunoPrecise Antibodies6.83%TVRDTvardi Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5062.12 million58.21 millionNot OptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableIPAImmunoPrecise Antibodies8046.15 million43.00 millionNot OptionableTVRDTvardi Therapeutics809.38 million9.09 millionN/AIPA, TVRD, AURA, and DRUG HeadlinesRecent News About These CompaniesTvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Recommendation of "Buy" by BrokeragesOctober 3, 2025 | marketbeat.comAbivax (NASDAQ:ABVX) and Tvardi Therapeutics (NASDAQ:TVRD) Head to Head AnalysisOctober 1, 2025 | americanbankingnews.comBTIG biotech analyst holds a dinner meetingSeptember 25, 2025 | msn.comTvardi Therapeutics (TVRD) Receives a Buy from Piper SandlerSeptember 22, 2025 | theglobeandmail.comTvardi Therapeutics (NASDAQ:TVRD) Stock Price Up 0.2% - Here's What HappenedSeptember 17, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Is In A Good Position To Deliver On Growth PlansAugust 31, 2025 | finance.yahoo.comTvardi Therapeutics to Participate in the Cantor Global Healthcare ConferenceAugust 21, 2025 | theglobeandmail.comTvardi Therapeutics expects cash to fund operations into Q4 2026August 15, 2025 | msn.comTvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last yearAugust 15, 2025 | msn.comTvardi: Q2 Earnings SnapshotAugust 14, 2025 | timesunion.comTTvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business UpdateAugust 14, 2025 | finance.yahoo.comRaymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform RecommendationJuly 15, 2025 | msn.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | finance.yahoo.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | businesswire.comCantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight RecommendationJuly 12, 2025 | msn.comTvardi Therapeutics Inc News (TVRD) - Investing.comJune 27, 2025 | investing.comTVRD Tvardi Therapeutics, Inc.June 19, 2025 | seekingalpha.comPiper Sandler initiates Tvardi Therapeutics stock with overweight ratingJune 13, 2025 | uk.investing.comRecently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock UpsideJune 12, 2025 | benzinga.comTvardi Therapeutics Inc (TVRD)June 7, 2025 | investing.comTvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary FibrosisMay 27, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Darden Restaurants: A Textbook Buy-the-Dip OpportunityBy Thomas Hughes | September 19, 2025Sprouts, Darden Offer High-Upside Setups for Risk-TakersBy Sam Quirke | September 26, 2025The New Brain of Business: UiPath Is Creating an AI RevolutionBy Jeffrey Neal Johnson | October 2, 2025IPA, TVRD, AURA, and DRUG Company DescriptionsAura Biosciences NASDAQ:AURA$5.76 -0.16 (-2.70%) Closing price 04:00 PM EasternExtended Trading$5.85 +0.09 (+1.55%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Bright Minds Biosciences NASDAQ:DRUG$50.83 -0.67 (-1.30%) Closing price 04:00 PM EasternExtended Trading$50.83 0.00 (0.00%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.ImmunoPrecise Antibodies NASDAQ:IPA$2.10 +0.17 (+8.55%) Closing price 09/3/2025Extended Trading$2.10 0.00 (0.00%) As of 09/3/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Tvardi Therapeutics NASDAQ:TVRD$40.28 +0.10 (+0.25%) As of 04:00 PM EasternCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
